MedTrace Logo

Study of GNS561 in Patients With Liver Cancer

NCT03316222 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-05-02

No results posted yet for this study

Summary

This is a first in human, open-label dose escalation study to investigate the safety, tolerability and pharmacokinetics of GNS561 in patients Primary and Secondary liver cancer

Conditions

Interventions

DRUG

GNS561

Escalating doses to be administered 3 times a week.

Sponsors & Collaborators

  • Genoscience Pharma

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-04
Primary Completion
2021-01-15
Completion
2022-04-25
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03316222 on ClinicalTrials.gov